AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC
A phase 2 trial of Ivonescimab, Carboplatin, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Akeso, active and no longer recruiting.
Overview
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC is a phase 2 interventional study registered as NCT05247684 by Akeso, with 90 participants enrolled, started 2022-02-20 and due to reach its primary completion in 2025-08-18. Interventions recorded: AK112, Carboplatin, Cisplatin, Paclitaxel. Conditions listed: Resectable Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Carboplatin, Small-cell lung cancer.
- TrialAK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Akeso, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Akeso, Small-cell lung cancer.
- TrialAK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer
Shares Ivonescimab, Akeso, Paclitaxel / nab-paclitaxel.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Paclitaxel / nab-paclitaxel, Cisplatin, Carboplatin, Small-cell lung cancer.
- TrialA Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer
Shares Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.